标准汉考克猪生物假体：帕多瓦大学的总体经验。
The standard Hancock porcine bioprosthesis: overall experience at the University of Padova.
作者信息
Gallucci V, Mazzucco A, Bortolotti U, Milano A, Guerra F, Thiene G
机构信息
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.
出版信息
J Card Surg. 1988 Sep;3(3 Suppl):337-45. doi: 10.1111/jocs.1988.3.3s.337.
All patients undergoing aortic (AVR, n = 196), mitral (MVR, n = 502), and mitral-aortic (MAVR, n = 71) valve replacement with a standard Hancock porcine bioprosthesis (HPB) from 1970 to 1983 were reviewed. A total of 665 patients discharged were followed for 5,099 patient-years with an actuarial survival at 15 years of 52% +/- 4.5%, for MVR, 37% +/- 14% for AVR, and at 12 years of 52 +/- 7.4% for MAVR. Embolic episodes occurred in 9 patients after AVR (0.7% +/- 0.2% pt-yr), in 61 after MVR (1.7% +/- 0.2% pt-yr), and in 6 after MAVR (1.7% +/- 0.7% pt-yr); actuarial freedom from emboli at 15 years is 91% +/- 3.5% after AVR, 79% +/- 14% after MVR, and at 12 years is 87% +/- 5% after MAVR. Reoperation because of primary tissue failure (PTF) was performed in 47 patients with AVR (3.9% +/- 0.5% pt-yr), 91 with MVR (2.6% +/- 0.3% pt-yr), and in 13 with MAVR (4.1% +/- 1.1% pt-yr); actuarial freedom from PTF at 15 years is 41% +/- 5.5% after MVR, 37% +/- 10% after AVR, and at 12 years is 49% +/- 13% after MAVR. After AVR and MVR, freedom from PTF is significantly better for patients over 50 years of age.(ABSTRACT TRUNCATED AT 250 WORDS)
对1970年至1983年期间使用标准汉考克猪生物瓣膜（HPB）进行主动脉瓣置换（AVR，n = 196例）、二尖瓣置换（MVR，n = 502例）以及二尖瓣 - 主动脉瓣置换（MAVR，n = 71例）的所有患者进行了回顾。共有665例出院患者接受了5099患者 - 年的随访，15年时MVR的精算生存率为52%±4.5%，AVR为37%±14%，MAVR在12年时为52%±7.4%。AVR后9例患者发生栓塞事件（0.7%±0.2%患者 - 年），MVR后61例（1.7%±0.2%患者 - 年），MAVR后6例（1.7%±0.7%患者 - 年）；AVR后15年无栓塞的精算自由度为91%±3.5%，MVR后为79%±14%，MAVR在12年时为87%±5%。因原发性组织衰竭（PTF）进行再次手术的患者，AVR有47例（3.9%±0.5%患者 - 年），MVR有91例（2.6%±0.3%患者 - 年），MAVR有13例（4.1%±1.1%患者 - 年）；MVR后15年无PTF的精算自由度为41%±5.5%，AVR后为37%±10%，MAVR在12年时为49%±13%。AVR和MVR后，50岁以上患者无PTF的情况明显更好。（摘要截短至250字）
Zotero 插件